Barchart.com's Chart of the Day - Sierra Oncology
Related Stocks
 SRRA - Sierra Oncology Inc
SymLastChgPct
SRRA1.88+0.05+2.73%
The Chart of the Day belongs to Sierra Onocology (SRRA).  I found the cancer drug development stock by using Barchart to sort the Top Stocks to Own list first by the highest Weighted Alpha, then I used the Flipchart feature to review the charts of consistent price appreciation.  Since the Trend Spotter signaled a buy on 10/24 the stock gained 87.89%.

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquartered in Vancouver, Canada.

srra

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

 

Barchart technical indicators:

  • 152.50+ Weighted Alpha
  • 100% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 8 new highs and up 38.37% in the last month
  • Relative Strength Index 77.59%
  • Technical support level at 3.26
  • Recently traded at 3.57 with a 50 day moving average of 2.45

Fundamental factors:

  • Market Cap $169 million
  • Earnings estimated to increase 46.20% this year, 4.70% next year and continue to compound at an annual rate of 59.80% for the next 5 years
  • Wall Street analysts issued 3 strong buy recommendations
  • The individual investors following the stock on Motley Fool voted 41 to 4 that the stock will beat the market